SoFi stock falls after announcing $1.5B public offering of common stock
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced the appointment of Weinberg & Company P.A. as its new independent registered public accounting firm for the fiscal year ending December 31, 2025. The decision was approved by the company’s audit committee on November 20.
Weinberg & Company had previously been engaged to audit the financial statements of Dura Medical LLC, which was acquired by Hope Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals. According to the company’s statement, neither NRx Pharmaceuticals nor its representatives consulted Weinberg & Company regarding the application of accounting principles, audit opinions, or any accounting, auditing, or financial reporting issues during the company’s two most recent fiscal years and the interim period through September 30, 2025.
On or around November 24, the audit committee dismissed Salberg & Company P.A. as the company’s independent registered public accounting firm. Salberg & Company’s audit reports on NRx Pharmaceuticals’ consolidated financial statements for the fiscal years ended December 31, 2024, and December 31, 2023, did not contain adverse opinions or disclaimers of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles, except for an explanatory paragraph regarding the company’s ability to continue as a going concern.
The company reported that during the two most recent fiscal years and the interim period through September 30, 2025, there were no disagreements or reportable events with Salberg & Company on matters of accounting principles, financial statement disclosure, or auditing scope or procedures.
As required, NRx Pharmaceuticals provided Salberg & Company with a copy of the current report and requested a letter addressed to the Securities and Exchange Commission stating whether Salberg agreed with the company’s disclosures. Salberg provided the requested letter, confirming its agreement with the statements made by NRx Pharmaceuticals.
This information is based on a statement from the company’s recent SEC filing.
In other recent news, NRx Pharmaceuticals announced its third-quarter 2025 earnings, marking a significant milestone with its first-ever revenue of approximately $240,000. This revenue was generated through its Hope Therapeutics clinic network, following the acquisition of Dura Medical in September. Despite this achievement, the company reported an operating loss of $4 million, an increase from the $3 million loss in the same quarter last year. NRx Pharmaceuticals currently holds $7.2 million in cash and cash equivalents, with expectations to fund operations through the third quarter of 2026. Additionally, the company has a potential increase in cash reserves to $10.3 million with a subscription receivable, which could extend operational funding through the second quarter of 2026. H.C. Wainwright has reiterated its Buy rating for NRx Pharmaceuticals, maintaining a price target of $40.00. The firm’s analysis reflects confidence in the company’s future prospects despite current financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.